

Vortex Biosciences, Inc. Places a VTX-1 System to Investigate PDX CTC Models with StemMed, Ltd. facility

November 14, 2019

Vortex Biosciences, a leading provider of circulating tumor cell (CTC) isolation systems and workflows, announces a placement of the VTX-1 Liquid Biopsy System at StemMed, Ltd, a state-of-the-art pre-clinical drug testing service facility. StemMed provides these services using a large panel of patient-derived xenograft (PDX) models of breast and pancreatic cancer.

Patient-derived xenograft (PDX) models have been verified as a useful method for studying human cancers in mice. PDX have been proven to shed CTCs into the bloodstream and metastasize. The announced placement will allow the fully automated VTX-1 to provide value with its ability to isolate cells of interest for downstream analysis.

About Vortex Biosciences

Vortex Biosciences integrates cancer biology, microfluidic engineering, and informatics to advance cancer research and accelerate the development of innovative diagnostics and therapeutics through tools for isolating intact CTCs. The fully automated Vortex VTX-1 instrument harvests intact circulating tumor cells from whole blood samples for use in downstream research and clinical applications such as patient stratification in clinical trials, monitoring disease progression and drug treatment effectiveness. With a mission to enable noninvasive diagnosis of cancer and real-time monitoring throughout a patient's treatment, Vortex is at the forefront of accelerating cancer research and improving patient outcomes. For more information, visit <http://www.vortexbiosciences.com>.

About StemMed, Ltd

StemMed is a pharmaceutical development and testing company located in Houston, Texas that seeks to advance the treatment of breast cancer through novel insights into the biology of the stem cells that drive tumor formation. We now understand that only a small subset of the heterogeneous cells within a malignant tumor is responsible for the initiation and maintenance of tumor growth. Therefore, we believe that specifically targeting such cells for therapeutic intervention will inhibit tumor formation, growth, and metastasis. We also believe that this approach may be particularly effective in the treatment of cancers that are resistant to conventional therapies. For more information, visit <http://stemmedcancer.com/about/>.